- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07832006
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
A Prospective Study of Irreversible Electroporation Combined With Lenvatinib and Sintilimab for Conversion Therapy in Patients With Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion surgery rate remain suboptimal. Irreversible electroporation (IRE) is a non-thermal ablation technique that can induce tumor cell death while preserving surrounding vascular and biliary structures. Emerging evidence suggests that IRE may enhance anti-tumor immunity and synergize with systemic therapy.
This prospective, single-center, open-label study aims to evaluate the efficacy and safety of IRE combined with lenvatinib and sintilimab in patients with advanced HCC. Eligible patients with unresectable CNLC stage IIa, IIb, or IIIa disease will receive standard targeted therapy and immunotherapy with or without IRE according to treatment allocation. The primary endpoints are objective response rate (ORR) and conversion surgery rate. Secondary endpoints include time to response (TTR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs).
The study is expected to provide evidence regarding the role of IRE in enhancing tumor response and increasing the likelihood of curative-intent surgical resection in patients with advanced HCC.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
-
Background
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. For patients with advanced-stage disease, systemic therapy based on tyrosine kinase inhibitors and immune checkpoint inhibitors has become the standard of care. However, only a proportion of patients achieve meaningful tumor regression, and the rate of successful conversion to surgical resection remains limited.
Irreversible electroporation (IRE) is a novel non-thermal local ablative technique that induces apoptosis through permanent disruption of cellular membranes. Unlike thermal ablation modalities, IRE preserves major blood vessels and bile ducts, making it particularly suitable for tumors adjacent to critical structures. Furthermore, preclinical and clinical studies have suggested that IRE may induce immunogenic cell death and augment anti-tumor immune responses.
-
Study Objectives
The primary objective of this study is to evaluate whether the addition of IRE to targeted therapy and immunotherapy improves tumor response and conversion surgery rate in patients with advanced HCC.
The secondary objective is to assess survival outcomes and treatment-related safety.
-
Study Design
This is a prospective, single-center, open-label interventional study. Patients with advanced HCC meeting the eligibility criteria will receive either:
IRE combined with lenvatinib and sintilimab; or Lenvatinib and sintilimab alone.
Tumor response will be evaluated according to RECIST version 1.1 and mRECIST criteria. Patients will undergo regular imaging assessments and multidisciplinary evaluation to determine eligibility for curative-intent surgical resection.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jiayue Li
- Phone Number: 010-69156874
- Email: pumchkyc@126.com
Study Locations
-
-
No. 1 Shuaifuyuan, Dongcheng District, Beijing, China
-
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Longfang Miao
- Phone Number: 010-69155709
- Email: pumchjyc@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 75 years.
- Clinically or pathologically confirmed hepatocellular carcinoma (HCC).
- Unresectable HCC corresponding to CNLC stage IIa, IIb, or IIIa, without extrahepatic metastasis.
- At least one measurable lesion according to RECIST version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Child-Pugh class A or B liver function.
- Adequate organ function, including an absolute neutrophil count ≥1.5 × 10⁹/L; platelet count ≥75 × 10⁹/L; hemoglobin ≥80 g/L; serum creatinine ≤1.5 × the upper limit of normal (ULN) or creatinine clearance ≥50 mL/min; total bilirubin ≤3 × ULN; and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN.
- Suitable for treatment with lenvatinib and sintilimab according to institutional standards.
- Able to understand and sign written informed consent.
Exclusion Criteria:
- Presence of extrahepatic metastasis.
- Previous treatment with irreversible electroporation.
- Prior systemic therapy that precludes treatment with lenvatinib or sintilimab.
- Diffuse infiltrative HCC not suitable for IRE evaluation.
- Uncontrolled ascites, hepatic encephalopathy, or active gastrointestinal bleeding.
- Active severe infection requiring systemic treatment.
- Active tuberculosis.
- Uncontrolled hepatitis B virus replication despite antiviral therapy.
- Clinically significant cardiovascular disease, including uncontrolled hypertension, recent myocardial infarction, unstable angina, or severe arrhythmia.
- Concurrent malignancy requiring active treatment.
- Pregnancy or breastfeeding.
- Any condition that, in the investigator's judgment, would interfere with study participation or interpretation of the study results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: IRE + Lenvatinib + Sintilimab
Patients receive irreversible electroporation combined with lenvatinib and sintilimab as conversion therapy. |
Percutaneous or intraoperative irreversible electroporation performed according to institutional standards. Oral administration according to body weight and prescribing information. 200 mg intravenously every 3 weeks. |
|
Active Comparator: Lenvatinib + Sintilimab
Patients receive standard targeted therapy and immunotherapy without IRE. |
Oral administration according to body weight and prescribing information. 200 mg intravenously every 3 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR)
Time Frame: From treatment initiation until conversion surgery, first documented disease progression, or treatment discontinuation, whichever occurs first, with tumor response assessed approximately every month, up to 24 months.
|
The proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST version 1.1. |
From treatment initiation until conversion surgery, first documented disease progression, or treatment discontinuation, whichever occurs first, with tumor response assessed approximately every month, up to 24 months.
|
|
Conversion Surgery Rate
Time Frame: From treatment initiation until curative-intent conversion surgery, disease progression, or treatment discontinuation, whichever occurs first, assessed up to 24 months.
|
Proportion of patients who undergo curative-intent surgical resection after study treatment based on multidisciplinary evaluation. |
From treatment initiation until curative-intent conversion surgery, disease progression, or treatment discontinuation, whichever occurs first, assessed up to 24 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-Free Survival (PFS)
Time Frame: Up to 24 months
|
Time from treatment initiation to disease progression or death. |
Up to 24 months
|
|
Overall Survival (OS)
Time Frame: Up to 24 months
|
Time from treatment initiation to death from any cause. |
Up to 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Digestive System Neoplasms
- Digestive System Diseases
- Liver Diseases
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Investigative Techniques
- Clinical Laboratory Techniques
- Cytological Techniques
- Electrochemical Techniques
- Electroporation
- sintilimab
- lenvatinib
Other Study ID Numbers
- I-24PJ2181
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.